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Background: Thymic epithelial tumors (TETs), which comprise thymoma and thymic carcinoma, are rare cancers
with specific morphological and clinical features. Their clinical characteristics and outcomes have gradually been
clarified by assessing large-scale, retrospective data obtained with international cooperation.
Methods: The study is a retrospective review of 187 Japanese patients with TETs who attended our institution from
1976 to 2012. Relevant clinical features of patients with TETs and their tumors, including histology, staging,
treatment strategies, and overall survival, were investigated. Differences in survival were assessed by the
Kaplan–Meier method and uni- and multi-variate Cox proportional hazards regression analyses.
Results: The 187 patients included 52 patients with stage I, 37 with stage II, 22 with stage III, and 76 with stage
IVa/IVb tumors according to the Masaoka–Koga Staging System. As to histological type, five patients had type A, 33
type AB, 19 type B1, 39 type B2, and 15 type B3 thymomas, whereas 68 patients had thymic carcinoma, including
11 with neuroendocrine carcinomas according to the 2004 WHO classification. Either insufficient data were available
to classify the tumors of the remaining eight patients or they had rare types. Immunological abnormalities were
present in 26 patients, most of whom had thymomas (21.8% of the thymoma group). Most of the patients who
presented with symptoms had myasthenia gravis or extensive thymic carcinoma. Secondary cancers were present
in 25 patients (13.3%). The overall 5- and 10-year survival rates for thymoma were 85.4 and 71.5%, respectively, and
those for thymic carcinoma were 33.8 and 2.3%, respectively. OS differed significantly between stage IVa thymomas
and thymic carcinomas. The stage and whether the tumors were thymomas or thymic carcinomas were significant
determinants of survival according to multivariate analysis.
Conclusion: The efficacy of treatments for thymoma and thymic carcinoma should be investigated separately
because these tumors differ in their clinical features and prognosis.
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Thymic epithelial tumors (TETs, or thymic malignancies)
which comprise thymoma and thymic carcinoma, are rare
cancers according to the definition of the RARECARE
project, which is supported by the European Commission.
Their annual incidence is approximately 0.15 cases in the
United States [1] and 0.32 cases in the Netherlands [2] per
100,000 person-years. Thymic malignancies are extremely
heterogeneous, with an exceedingly broad spectrum of
morphological appearances and immunological abnormal-
ities. Because thymomas are bioactive and have organoty-
pic features that lead to autoimmune manifestations,
whereas thymic carcinomas are not immunologically ac-
tive and lack organotypic features, patients with thymic
carcinoma usually have symptoms associated with tumor
extension or metastasis.
Because of their rarity, the clinical characteristics and
prognostic indicators in patients with thymic malignan-
cies have not been well characterized [3]. Therefore, the
International Thymic Malignancy Interest Group (ITMIG)
was organized. Despite the paucity of evidence, this group
has reached consensus agreements in support of some
treatment modalities, having conducted some single-arm
phase II studies and a few retrospective studies of small
groups of treated patients with diverse backgrounds [4].
However, the optimal therapeutic strategy remains contro-
versial. In previous studies, patients with thymoma and
thymic carcinoma have basically received the same treat-
ment. However, it has recently been suggested that the
two types of tumors should be considered separate en-
tities [5]. In addition, the ITMIG has proposed using the
Masaoka–Koga staging system [6] and the 2004 World
Health Organization (WHO) histological classification;
both proposals have been accepted [7]. Thus, we believe
it is necessary to review and clarify the nature and charac-
teristics of these clinical entities in light of the proposed
criteria. Furthermore, the National Comprehensive Cancer
Network has updated its guidelines for the clinical man-
agement and treatment of thymic malignancies, despite
their rarity [8].
The objective of the present study was to retrospectively
clarify the clinical characteristics, prognosis, and prognos-
tic indicators of patients with thymoma and thymic car-
cinoma according to the 2004 WHO classification [7] who
had attended our institution over a 30-year period.
Methods
Database
This is a retrospective review of patients diagnosed with
thymic malignancies between January 1976 and December
2012 identified from the databases at Tokyo Metropolitan
Cancer and Infectious diseases Center Komagome Hos-
pital (Tokyo, Japan). The codes of the International Classi-
fication of Diseases (9th edition) were used.This retrospective study was approved by the Ethics
Committee of the Tokyo Metropolitan Cancer and In-
fectious diseases Center Komagome Hospital (#1049).
Patients and histological evaluation
A retrospective review of relevant clinical features and
treatment-related data of 187 consecutive Japanese patients
with diagnoses of thymic malignancies was performed.
Their pathology was reviewed by a thoracic pathologist
(TH) according to the 2004 WHO classification and
Masaoka–Koga staging system [6]. Diagnoses of thymic
carcinoma were confirmed by hematoxylin-eosin stain-
ing and immunohistochemistry for CD5 and/or CD117
(c-KIT) and/or p63 to exclude other malignant thoracic
tumors, as well as supplemental testing for terminal
deoxynucleotidyl transferase to distinguish carcinomas
from thymomas. Clinical factors were also examined.
Data were collected in accordance with the Standard
Definitions and Policies of the ITMIG [4].
Clinical factors including age, sex, histological subtype,
stage, immunological abnormalities, secondary malignan-
cies, initial treatment -intent of modality, and survival
were examined, relevant data having been obtained from
medical records and laboratory data. Staging had been de-
termined according to the Masaoka–Koga staging system
by computed tomography, magnetic resonance imaging,
positron emission tomography, or bone scanning. Hist-
ology was also classified according to the 2004 WHO
classification. The patients had been treated with curative-
intent or palliative-intent surgery, radiotherapy, chemo-
therapy, and best supportive care, or a combination of
these modalities.
Statistical analysis
Descriptive statistics were used to summarize the pa-
tients’ baseline characteristics. Survival time was defined
as the period from the date of initiation of initial treat-
ment (surgery, radiotherapy, chemotherapy, or best sup-
portive care) to the date of death from any cause or last
follow-up. The Kaplan–Meier method was used to assess
overall survival and 5- and 10-year survival rates. Pa-
tients who had been lost to follow-up were censored at
the time of last contact. These end points reflected clin-
ical practice because of the retrospective nature of the
data. In accordance with the ITMIG Standard Definitions
and Policies, the 5-year survival rate of patients with
thymic carcinomas and 10-year survival rate of those with
thymoma were calculated. Correlations between histo-
logical subtype according to the 2004 WHO classification
and Masaoka–Koga stage were evaluated using a nonpara-
metric measure of statistical dependence between the two
variables.
The log-rank test was used to identify prognostic indica-
tors by uni- and multi-variate analysis. Candidate variables
Table 1 Characteristics of patients and tumors in patients with thymic malignancies
Characteristics Thymoma Thymic carcinoma
n = 119 (%) n = 68 (%)
Median age, Years [range] 58 [26–81] - 63 [14–83] -
Gender
Male 52 43.7 38 55.9
Female 67 56.3 30 44.1
Histology
Thymomas 119 100.0
Type A 5 4.2
Type B1 19 16.1
Type B2 39 32.8
Type B3 15 12.6
Type AB 33 27.7
Other subtypes or missing data of thymoma 8 6.7
Thymic carcinomas 68 100.0
Squamous cell carcinoma 46 67.6
Mucoepidermoid carcinoma 5 7.4
Lymphoepithelioma-like carcinoma 1 1.5
Undifferentiated carcinoma 3 4.4
Neuroendocrine carcinomas 11 16.2
Small cell carcinoma 3 4.4
LCNEC 2 2.9
Carcinoid 6 8.8
Not classified in WHO classification 2 2.9
Staging
I 52 43.7 0 0
II 31 26.1 6 8.8
III 12 10.1 10 14.7
IVa 18 15.1 16 23.5
IVb 6 5.0 36 52.9
Complications
Immunological abnormalities (overlapped)
Myasthenia gravis 20 16.8 1 1.5
Pure red cell aplasia 4 3.3
Hypogammaglobulinemia 5 4.2
Secondary malignancies 12 10.1 13 19.1
Initial treatment-intent of modalities
Curative-intent treatment 116 97.5 43 63.2
Surgery 109 91.6 30 44.1
Surgery alone 89 74.8 10 14.7
Surgery with perioperative treatment 20 16.8 20 29.4
Radiotherapy 7 5.9 13 19.1
Definitive radiotherapy alone 1 0.8 1 1.5
Okuma et al. BMC Cancer 2014, 14:349 Page 3 of 9
http://www.biomedcentral.com/1471-2407/14/349
Table 1 Characteristics of patients and tumors in patients with thymic malignancies (Continued)
Chmoradiotherapy (sequential/concurrent) 6 5.1 12 17.6
Palliative-intent treatment 3 2.5 25 36.8
Chemotherapy alone 2 1.7 24 35.3
Best supportive care 1 0.8 1 1.5
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female), staging, immunological abnormalities, secondary
malignancies, and histological subtype according to the
WHO classification 2004. Significance according to
univariate analysis and multivariate Cox proportional
hazard models was defined as p < 0.05. All statistical
analyses were performed using JMP9 (SAS Institute,
Cary, NC, USA).Figure 1 Kaplan–Meier curves showing median overall survival
for thymoma (n = 119) was 235.2 months (95% CI, 137.3-not
reached) and for thymic carcinoma (n = 68) 32.4 months (95%
CI, 23.7–52.2) (p < 0.0001). The 5 year-survival for thymoma and
thymic carcinoma was 85.4 and 33.8%, respectively.Results
Characteristics of patients with thymoma and thymic
carcinoma and their tumors
Of the 187 patients, 119 (52 men, 67 women) had thym-
omas and 68 (38 men, 30 women) had thymic carcin-
omas. Their median age was 58 years for thymoma and
63 years for thymic carcinoma. As to histology, accord-
ing to the 2004 WHO classification five patients had
type A, 19 type B1, 39 type B2, 15 type B3, and 33 type AB
thymomas. Of the 68 patients with thymic carcinoma, 11
(16.2%) had neuroendocrine carcinomas (three small cell
carcinomas, two large cell neuroendocrine carcinomas,
and six carcinoid tumors), 46 squamous cell carcinomas
(67.6%), five mucoepidermoid carcinomas (7.4%), and one
a lymphoepithelioma-like carcinoma. The remaining eight
patients either had other histological types or relevant data
were unavailable. Only a patient with thymic carcinoma
had autoimmune-related manifestations. Most of the
patients who presented with symptoms had myasthenia
gravis or thymic carcinoma. Secondary malignancies
were seen in 25 patients (13.4%). At the time of diagno-
sis, 52 thymoma patients (43.7%) had stage I, 31 (26.1%)
stage II, 12 (10.1%) stage III, and 24 (20.1%) stage IVa/
IVb according to the Masaoka–Koga Staging System,
whereas six thymic carcinoma patients (8.8%) had stage
II disease, 10 (14.7%) stage III disease, 16 (23.5%) stage
IVa disease, and 36 stage IVb disease (52.9%). A variety
of immunological paraneoplastic abnormalities were
observed in the 26 patients with thymomas (21.8%).
There was some overlap among patients with immuno-
logical abnormalities.
Relevant patients’ characteristics are summarized in
Table 1. The median follow-up for all 187 patients at
the time of analysis was 43.9 months (range: 0.3–
404.8 months).Treatment modalities and strategies for thymoma and
thymic carcinoma
Initial treatment was performed with curative-intent in
97.5% of patients with thymoma (surgery in 91.6%, radio-
therapy in 5.9%) and in 63.2% of those with thymic carcin-
oma (surgery in 44.1%, radiotherapy in 19.1%).
The types of treatment modality are also summarized
in Table 1.Clinical outcomes of thymoma and thymic carcinoma by
stage and histological classification
Stage
The overall median OS of patients with thymoma was
235.2 months (95% CI, 137.3-not reached), whereas that of
those with thymic carcinoma was 32.4 months (95% CI,
23.7–52.2) (p < 0.0001) (Figure 1). The survival of patients
with stages I, II, III, IVa, and IVb thymoma was not
reached, not reached, 171.8, 110.1, and 83.8 months, re-
spectively. The 5- and 10-year survival rates of patients with
thymoma were 85.4 and 71.5%, respectively (Figure 2b-d).
Conversely, survival of patients with stages II, III, IVa,
and IVb thymic carcinoma was 78.9, 56.4, 27.3, and
21.7 months, respectively (Figure 2b-d). The 5- and 10-
year survival rates of patients with thymic carcinoma
were 33.8 and 2.3%, respectively.
Figure 2 Survival curves by histological subtypes. (a) Kaplan–Meier survival curves for each histological subtype of the WHO classification.
(b) Overall survival by stage for patients with thymic malignancies. (c), (d) stratified by stage in thymoma and thymic carcinoma
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The 5- and 10-year survival rates were 100% and cen-
sored for patients with type A, 96.3 and 73.8% for those
with type AB, 90.9% and 68.2 for those with type B1,
79.8 and 67.3% for those with type B2, and 61.6 and
61.6% for those with type B3, respectively (Figure 2a).
The median OS of patients with thymic carcinoma was
36.4 months (95% CI, 23.7-52.2) for all stages combined,
whereas the 5- and 10-year survival rates were 36.3 and
2.3%, respectively. The median OS of patients with
high-grade histology was 24.7 months, whereas that for
patients with low-grade histology was 36.8 months. The
overall median survival of patients with neuroendocrine
carcinoma was 43.9 months. The median survival of the
six patients with well-differentiated neuroendocrine
carcinoma was 36.4 months (95% CI 7.5–92.0) with a
5-year survival of 20.0%, whereas it was 43.9 months
(95% CI 5.6–127.4) in the five patients with poorly-
differentiated neuroendocrine carcinoma, with a 5-year
survival of 20.0%.
Correlation between tumor type according to the 2004
WHO classification and Masaoka–Koga stage
The distribution of the WHO classification and Masaoka–
Koga stage of the 187 patients is shown in Table 2. The
proportions of advanced stages (Masaoka–Koga stages III,
IVa, and IVb) increased gradually from Type A thymoma
to thymic carcinoma. There was a significant correlationbetween the WHO classification and Masaoka–Koga stage
(Spearman’s rank correlation coefficient = 0.69, p < 0.0001).
Prognostic factors affecting survival according to uni- and
multi-variate analysis
According to univariate analysis, age and all Masaoka–
Koga stages were significantly correlated with survival in
patients with thymoma. However, this was not the case
in those with thymic carcinoma. According to multivari-
ate analysis, early stages (Masaoka-Koga stage I or II)
and advanced stages (IVa or IVb) of both thymomas and
thymic carcinomas correlated significantly with survival
(Table 3).
Discussion and conclusion
The present retrospective analysis examined the clinical
outcomes of 187 patients with thymic malignancies. The
clinical characteristics and outcomes in these unselected
subjects were similar to those previously reported from
large, multi-institutional series.
Based on the Müller–Hermelink classification [9], the
WHO classification of thymomas was first proposed in
1999 [10]. In the 2004 WHO classification, thymic
carcinoma, including neuroendocrine carcinoma, was
separated from thymoma and given a new category [7].
Thymomas are classified into five groups: A, AB, B1,
B2, and B3. According to retrospective studies, Types A
and AB have a better prognosis than B1, B2, B3, and
Table 2 Relationships between overall survival and WHO histological subtype according to the Masaoka–Koga
staging system
WHO classification (2004) No of Pts Masaoka-Koga Stages Survival rates (%)
(%) I II III IVa IVb 5-yr OS 10-yr OS
Thymoma 119 52 31 12 18 6 85.4 71.5
A 5 2.7 4 1 0 0 0 100 -
AB 33 17.6 21 8 1 2 1 96.3 73.8
B1 19 10.2 11 5 0 2 1 90.9 68.2
B2 39 20.9 12 9 8 8 2 79.8 67.3
B3 15 8.0 1 5 3 5 1 61.6 61.6
Thymoma, other 8 4.3 3 3 0 1 1 68.6 68.8
Thymic carcinoma 68 36.4 0 6 10 16 36 33.8 2.3
Thymic carcinoma excluding NEC 57 30.5 0 5 9 13 30 33.0 4.1
NETT 11 5.9 0 1 1 3 6 27.3 9.1
Total 187 100.0 52 37 22 34 42 65.9 45.3
WHO, World Health Organization; OS, overall survival; NETT, neuroendocrine thymic tumors.
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to identify a correlation between survival and WHO clas-
sification [14-16]. These results were discussed as limita-
tions owing to the difficulty in accurate reproducibility
when diagnosing thymic malignancies with the WHO
schema. However, clinical features such as immuno-
logical abnormalities and secondary malignancies may
contribute to prognosis. Although our results did not
demonstrate a significant association between abnor-
malities or secondary malignancies and survival, some
studies have reported that types A and AB thymoma
have a low association with myasthenia gravis, whereas
types B1 and B2 are more likely to be associated with
myasthenia gravis. Up to 45% of patients with thymoma
develop myasthenia gravis [17,18]. According to the
WHO classification, there are 13 subtypes of thymic car-
cinoma; 60–70% of all thymic carcinomas being subtypes
of squamous cell carcinoma and lymphoepithelioma-like
carcinoma. Recent biomarker investigations have explored
c-KIT as a characteristic of thymic carcinoma [19]. Clin-
ically, thymomas and thymic carcinomas have different
patterns of recurrence: thymomas mainly result in
pleural dissemination as opposed to the distant metas-
tases characteristic of thymic carcinoma [20]. The
WHO classification still has some limitations, in that
distinguishing even thymoma and thymic carcinoma
subtypes remains difficult. As to staging systems, the
Masaoka–Koga staging system is widely accepted for
both thymoma and thymic carcinoma, which is prob-
lematic because incorrect diagnoses, confounding of
clinical entities, and intermingled management tend to
occur. Till today, only a few studies according to the
2004 WHO Classification and Masaoka-Koga stage have
been published (Table 4).The present study is based on a relatively large database
including all treated cases from the department of surgery,
medical oncology, and radiation oncology. Additionally,
we found that thymomas and thymic carcinomas exhib-
ited a variety of clinical behaviors as reported in the past
study. We believe that our single-institution data are reli-
able in that all cases were diagnosed by a pathologist who
authored the thymic carcinoma section of the WHO
classification book [7]. The lack of correlation between
survival and WHO classification in thymomas may be at-
tributable to the small numbers of patients studied, im-
munological abnormalities, or too few events because of
the characteristically long survival. In our study, patients
with thymomas had a similar prognosis to that previously
reported, whereas both indolent and aggressive clinical
courses occurred in patients with thymic carcinomas, in-
cluding thymic squamous cell carcinoma. In neuroendo-
crine thymic tumors (or carcinomas) (NETT), the present
small cohort of well-differentiated and poorly differenti-
ated NETT showed similar clinical behavior to that re-
ported in previous studies [21]. In the present study, no
patients with NETT developed multiple endocrine neo-
plastic syndrome. As previously reported for NETT, the
prognosis in this subgroup was poor [22]. The clinical en-
tity of NETT is gradually becoming better known: the
European Society of Medical Oncology has already pub-
lished guidelines for NETT [23].
The key limitation of the present study was the small
numbers of patients in each stage of thymoma or thymic
carcinoma, resulting in a paucity of data compared with
that obtained in randomized trials. However, this is a
common limitation of studies of rare cancers. Second,
we were unable to follow patients up, particularly young
patients with thymoma or early stages of carcinoma whose
Table 3 Uni- and multi-variate analysis of survival in patients with thymic malignancies
Univariate analysis
Variants Thymoma Thymic carcinoma
n MST [95% CI] p-value n MST [95% CI] p-value
Age (y)
0.0018* 0.36<70 91 71.3 [54.4-88.1] 50 24.1 [13.5-43.6]
≥70 28 30.1 [13.8-59.9] 18 24.6 [11.9-36.4]
Gender
0.29 0.076Male 52 235.2 [136.8-NR] 38 29.7 [13.5-40.2]
Female 67 171.8 [110.1- NR] 30 56.4 [23.7-73.0]
Masaoka-Koga Stage
0.0012* 0.18
I 52 NR [136.8- NR] 0 -
II 31 NR [NR - NR] 6 78.9 [65.8-92.0]
III 12 171.8 [4.7- NR] 10 56.4 [8.8-99.6]
IVa 18 110.1 [33.8-235.2] 16 27.3 [17.2-43.9]
IVb 6 83.8 [0.6- NR] 36 21.6 [11.3-36.4]
Immunological abnormalities
0.26 0.59Yes 26 NR [171.8- NR] 2 71.2 [69.5-73.0]
No 93 156.6 [126.3- NR] 66 30.4 [23.6-43.9]
Secondary Malignancies
0.42 0.54Yes 12 235.2 [74.4-235.2] 13 36.8 [5.8-65.8]
No 107 171.8 [136.8- NR] 55 30.4 [21.6-56.4]
WHO classification [thymoma]
0.68
A 5 79.2 [−]
AB 33 - [91.6- NR]
B1 19 - [126.3- NR]
B2 39 171.8 [110.1- NR]
B3 15 - [37.2- NR]
Other 8 235.2 [4.4-235.2]
[thymic carcinoma]
0.95High grade 52 36.8 [23.7-65.8]
Low grade 16 24.7 [8.5-66.6]
Multivariate analysis
Variants Thymoma Thymic carcinoma
HR 95% CI P-value HR 95% CI p-value
Staging IVa/ I: 4.62 [1.78-13.37] 0.016*
II/IVa: 0.27 [0.43-0.99] 0.048*IVa/II: 6.40 [2.03-28.17] 0.001*
IVb/II: 5.56 [1.02-30.20] 0.047*
Immunological abnormalities 2.0 [0.73-6.35] 0.18
Secondary Malignancies 4.4 [0.63-51.9] 0.26 1.36 [0.57-3.28] 0.44
WHO Classification
(A/B1/B2/B3/AB/other) none none none - - -
(high grade vs. low grade) - - - 0.88 [0.46-1.57] 0.70
(thymic ca. vs. thymoma) 6.7 4.1-11.1 < .0001* - - -
NR, not reached; CI, confidence interval; MST, median survival time; HR, hazard ratio; CI confidence interval; *p < 0.05.
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Table 4 Previously reported and present study survival rates of patients with thymic malignancies by Masaoka–Koga
stage and 2004 WHO Classification
Reference No. of pts MST
(mo)







I II III IVa IVb
de Jong et al. [2] 203* N/A 82.9 (12.3) 87.8 (36.9) 57.6 (26.1) 55.6 (24.6) 69 40 Resection, Age
WHO classification
Masaoka disease stage
Masaoka et al. [29] 93* N/A 92.6 (39.8) 85.7 (13.8) 69.6 (34.4) 50.0 (11.8) 74.1 57.1 N/A
Mariano et al. [30] 171* N/A 93.3 (9.4) 88.7 (44.4) 74.6 (27.5) 43.4 (18.7) N/A N/A Masaoka-Koga stage
thymoma vs. thymic ca
JART study [31] 2807 N/A 97.7 (34.6) 95.8 (36.0) 85.8 (15.7) 72.8 (6.5) 57.4 (5.2) N/A N/A N/A
Present study 187 99.6 NR (27.3) NR (20.3) 99.6 (12.1) 59.2 (18.2) 24.8 (22.5) 65.9 45.3 Masaoka-Koga Stage II
thymoma vs. thymic ca
pts, patients; MST, median survival time; yrs, years; N/A, not available; *available data on survival is summarized.
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abnormalities. Thus, there were more censored patients in
the thymoma cohort than in the carcinoma cohort.
Large-scale databases are being established in Japan,
the USA, and Europe as a first step toward conquering
thymic malignancies. This approach appears to be a role
model for studying rare diseases. Because these databases
are drawn from surgical cases, they will provide little data
on the clinical entities of thymic malignancies. Therefore,
single-institution databases, such as that used in this
study, are still meaningful because of the consistency of
treatment and pathological evaluation; the latter would re-
sult in more reliable and reproducible diagnoses of thymic
malignancies. Nevertheless unified, multi-institutional da-
tabases centered on the ITMIG are indispensable. Studies
using such databases will clarify the clinical entities of and
evolve treatment strategies for rare cancers such as thymic
malignancies, which tend to fall behind in treatment de-
velopment compared with common cancers. To minimize
the biases from limited data concerning the reliability of
diagnosis or treatment, every strategy must be carried out
to overcome obstacles owing to the rarity of the cancer.
Plans are being made for prospective clinical trials on
this rare cancer. However, the inevitably small sample
size of future phase II studies will likely mean they have
insufficient power to establish that findings are signifi-
cant. In addition, as Weksler et al. have pointed out, a
fundamental problem still remains in that the diagnosis
of thymic malignancies, especially thymic carcinomas, is
difficult [24]. In fact, in the WJTOG 4207L trial [25],
25% of patients diagnosed with thymic carcinoma by
local hospitals were found to have incorrect diagnoses
when centrally reviewed. Thus, central review of diagno-
ses is essential and the results of such studies must be
interpreted with care. Investigators who plan clinical tri-
als of thymic malignancies should incorporate centralreview by reliable pathologists who have experience with
thymic malignancies. The importance of central review
in clinical trials on rare cancers was demonstrated in the
multi-institutional clinical trial of imatinib for c-Kit or
platelet-derived growth factor receptor (PDGFR) positive
sarcoma. In this trial, the concordance rate between the
trial sites and central review for immunohistochemical
staining was only 63.3% [26]. Also, the guidelines for
gastrointestinal stromal tumors (GISTs) recommend tak-
ing care with the diagnosis of c-Kit-negative GIST, which
requires consulting a specialist in GISTs who has experi-
ence in additional antibody staining or c-Kit or PDGFR
gene analysis [27,28].
In summary, the further clinical management of thym-
oma and thymic carcinoma should be investigated separ-
ately because of the clinical differences between thymoma
and thymic carcinoma. Moreover, a detailed population-
based series that highlights the many challenges clinicians
face when treating thymic malignancies, for which little
evidence-based data concerning therapy is available. Also,
the advantages and disadvantages of a single-institutional
database, especially on rare cancers, such as that used in
this study, have been discussed. Although there have
been advances in surgical techniques, radiation plan-
ning, systemic therapy, and supportive care for patients
with thymic malignancies, more research and collabora-
tive efforts are needed to produce evidence-based guide-
lines. International database projects and multidisciplinary
meetings supported by the ITMIG will undoubtedly help
fulfill this need.
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